Advertising Information

Kidney Cancer Journal is the Official Journal
of the Kidney Cancer Association

Kidney Cancer Journal Fact Sheet

  • Kidney Cancer Journal is the Official Journal of the Kidney Cancer Association
  • Kidney Cancer Journal is the only peer-reviewed medical journal and most comprehensive source of scientific information focusing exclusively on renal cell carcinoma
  • Robert A. Figlin, MD, Editor-in-Chief. Principal investigator on numerous kidney cancer clinical trials. Professor and Department Chair, Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, California
  • Published quarterly since December, 2003
  • Distributed as a complimentary professional service to 25,512 physicians, including all medical oncologists, hematologist-oncologists and urologists in U.S.
  • Utilizes a Medical Advisory Board and Editorial Advisory Board of more than 30 physicians who are leading investigators in this field
  • CME credit in each issue offered through City of Hope National Medical Center, Duarte, California
  • Archives available through the KCA’s website
  • Special Reports and supplements covering ASCO and highlights from the annual International Kidney Cancer Association Meeting
  • Program pricing available upon request

The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals. We fund, promote, and collaborate with the National Cancer Institute (NCI), American Society for Clinical Oncology (ASCO), American Urologic Association (AUA), and other institutions on research projects. They educate families and physicians, and serve as an advocate on behalf of patients at the state and federal levels.

The Kidney Cancer Association was founded in 1990 by a small group of patients, including Eugene P. Schonfeld, Ph.D., and medical doctors in Chicago, Illinois. It is a nonprofit charity incorporated in the State of Illinois. It has also been designated as a tax exempt organization under Section 501(c)(3) of the U.S. Internal Revenue Service code. Donations to the Association are tax deductible.

The Kidney Cancer Association is a member of, and is certified by, the National Health Council as an organization in full compliance with the Standards of Excellence for voluntary health agencies.

The Kidney Cancer Association is developing a global presence and is creating websites in several languages, including Chinese, Japanese, Spanish, German, French, Italian and other languages. New patient support groups are planned for the European Union, Asia and Australia in 2007.


Kidney Cancer Journal Ad Insertion Requirements
A letter of agreement is required to confirm all insertion orders negotiated for space within the Kidney Cancer Journal. The letter will specify the net cost, date of publication, number of pages as set forth in the client’s insertion and will stipulate color where applicable, and provide for prescribing information as required by regulatory agencies. All insertion orders for ads will be in compliance with the ad specifications as stipulated by the Kidney Cancer Journal. The letter of agreement will stipulate a materials due date for submission of an ad to the journal. 

An insertion order with purchase order number, if required by the client, must be submitted to the journal to confirm placement of an ad. Any changes to such ad must require prior review and written approval by the client prior to any changes made and used. A proof of the ad within the journal’s layout will be submitted for approval to the client’s compliance team prior to publication. Approval of such proof must be received by the journal two weeks prior to the publication date. Any change to or cancellation of an ad insertion within two weeks of the publication date will incur a charge of 50% of the net price of the insertion. 

Following publication, tearsheets and invoice will be provided. – payable net 30 days after receiving an undisputed invoice by the client. All insertion orders are governed by the terms and conditions located at:

Ad specifications:

Color: 4 color (CMYK)

Trim size: 8.375 x 10.875

Bleed: 1/8″  (8.625 x 11.125)

Live area: 7″ x 10″

Line screen: 175

Maximum density: 300

For spreads, trim size is 10.875 x 16.75, with live area of 10 x 15.5

Please send all files as press-quality PDF files, with crop marks, bleeds, and a color proof for matching with final press proofs.

All materials can be sent to this email address:
•  High-resolution (300 dpi) TIFF files and color proof


Communications Interactions
Kidney Cancer Journal 

Communications Interactions
Connect with Professionals
• Clinical Trial Recruitment
• Live Events: Symposia, Grand Rounds
• Podcasts
• Product Advertising
• Customized Educational Programs

Communications Interactions
Connect with Patients
• Clinical Updates
• News from Industry
• Side-effects Awareness & Management
• Compliance
• Concurrent Condition Awareness & Management
• Care-giver Support
• Newsletters

Common Issues Associated
with RCC Therapy

• Hypertension
• Pain Management
• Dehydration
• Nutrition
• Fatigue
• Sleep Disorders
• Depression

Communications Opportunities
Print and Website Advertising
• Reprints
• Sponsored Subscriptions
• Newsletters
• Supplements
• CME Grants
• Live Events
• Patient Education Programs
• Customized Programs

Current and Past Supporters
• Sutent (Pfizer)
• Nexavar (Bayer/Onyx)
• A.R.I.S.E.R. (Wilex)
• R.E.C.O.R.D. – 1 (Novartis)
• Proleukin (Novartis/Chiron)
• Zometa (Novartis)
• TargetmTOR (Novartis)
• Clinical Trial Recruitment (GSK)
• T.A.R.G.E.T.S. (Bayer/Onyx)
• Oncophage (Antigenics)
• ASCO (Bayer/Onyx)
• Temsirolimus (Wyeth)
• CME Activity (Wyeth)
• Genentech (Corporate)
• Torisel (Wyeth)

Kidney Cancer Journal 
The Team
• Robert A. Figlin, MD – Editor-in-Chief
• Stu Chapman – Executive Editor
Susan Hirschhaut – Director of Strategic Initiatives
• Jenny Chapman – Assoc. Dir, Editorial Services
• Michael McClain – Design Director